Aquestive Therapeutics, Inc. (AQST)
USD 3.0
(0.0%)
USD 3.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.87 Million USD | 86.93% |
| 2022 | -60.2 Million USD | 33.14% |
| 2021 | -90.03 Million USD | -37.75% |
| 2020 | -65.36 Million USD | 10.04% |
| 2019 | -72.65 Million USD | -18.38% |
| 2018 | -61.37 Million USD | -586.3% |
| 2017 | -8.94 Million USD | 6.86% |
| 2016 | -9.6 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.74 Million USD | 78.6% |
| 2024 Q1 | -12.82 Million USD | -58.16% |
| 2024 Q3 | -11.5 Million USD | -319.27% |
| 2023 Q2 | -5.79 Million USD | -130.0% |
| 2023 Q1 | 19.3 Million USD | 206.38% |
| 2023 FY | -7.87 Million USD | 86.93% |
| 2023 Q4 | -8.11 Million USD | -298.57% |
| 2023 Q3 | -2.03 Million USD | 64.87% |
| 2022 FY | -60.2 Million USD | 33.14% |
| 2022 Q1 | -16.7 Million USD | 42.3% |
| 2022 Q4 | -18.14 Million USD | -44.78% |
| 2022 Q3 | -12.53 Million USD | 36.82% |
| 2022 Q2 | -19.84 Million USD | -18.8% |
| 2021 FY | -90.03 Million USD | -37.75% |
| 2021 Q1 | -14.67 Million USD | 27.97% |
| 2021 Q2 | -12.36 Million USD | 15.71% |
| 2021 Q3 | -14.55 Million USD | -17.69% |
| 2021 Q4 | -28.94 Million USD | -98.87% |
| 2020 Q4 | -20.36 Million USD | -23.06% |
| 2020 Q2 | -2.33 Million USD | 85.88% |
| 2020 FY | -65.36 Million USD | 10.04% |
| 2020 Q1 | -16.53 Million USD | -30.82% |
| 2020 Q3 | -16.55 Million USD | -609.13% |
| 2019 Q2 | -20.47 Million USD | -39.02% |
| 2019 FY | -72.65 Million USD | -18.38% |
| 2019 Q4 | -12.63 Million USD | 31.37% |
| 2019 Q3 | -18.41 Million USD | 10.06% |
| 2019 Q1 | -14.72 Million USD | -5.61% |
| 2018 Q2 | -36.49 Million USD | -990.29% |
| 2018 FY | -61.37 Million USD | -586.3% |
| 2018 Q4 | -13.94 Million USD | 7.27% |
| 2018 Q3 | -15.03 Million USD | 58.79% |
| 2018 Q1 | 4.09 Million USD | 140.83% |
| 2017 Q2 | -5.89 Million USD | -304.74% |
| 2017 Q3 | 8.45 Million USD | 243.31% |
| 2017 Q1 | -1.45 Million USD | 0.0% |
| 2017 Q4 | -10.04 Million USD | -218.8% |
| 2017 FY | -8.94 Million USD | 6.86% |
| 2016 FY | -9.6 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 141.909% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 116.343% |
| Cosmos Health Inc. | -18.54 Million USD | 57.557% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 60.762% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 96.239% |
| Cronos Group Inc. | -73.96 Million USD | 89.36% |
| Incannex Healthcare Limited | -18.45 Million USD | 57.365% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 81.35% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 165.512% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -82.945% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -74.654% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -74.654% |
| SCYNEXIS, Inc. | 67.04 Million USD | 111.739% |
| Safety Shot Inc | -15.08 Million USD | 47.822% |
| Theratechnologies Inc. | -23.95 Million USD | 67.149% |
| Alpha Teknova, Inc. | -36.78 Million USD | 78.603% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -27.696% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 118.758% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -62.771% |
| Dynavax Technologies Corporation | -6.38 Million USD | -23.18% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.215% |
| Radius Health, Inc. | -25.79 Million USD | 69.485% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -153.991% |
| Alvotech | -551.73 Million USD | 98.574% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 94.365% |
| SIGA Technologies, Inc. | 68.06 Million USD | 111.562% |
| Shineco, Inc. | -22.44 Million USD | 64.943% |
| Silver Spike Investment Corp. | 7.34 Million USD | 207.219% |
| Journey Medical Corporation | -3.85 Million USD | -104.256% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 3.592% |
| Embecta Corp. | 70.4 Million USD | 111.179% |
| Harrow Health, Inc. | -24.41 Million USD | 67.76% |
| Procaps Group, S.A. | 42.54 Million USD | 118.5% |
| Biofrontera Inc. | -20.13 Million USD | 60.906% |
| DURECT Corporation | -27.62 Million USD | 71.51% |
| PainReform Ltd. | -9.34 Million USD | 15.775% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 698.024% |
| OptiNose, Inc. | -35.48 Million USD | 77.82% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 132.907% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 259.151% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -25.332% |
| ProPhase Labs, Inc. | -16.78 Million USD | 53.105% |
| Phibro Animal Health Corporation | 2.41 Million USD | 425.745% |
| Procaps Group S.A. | 42.54 Million USD | 118.5% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 23.429% |
| Viatris Inc. | 54.7 Million USD | 114.388% |
| Rockwell Medical, Inc. | -8.43 Million USD | 6.743% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 50.328% |
| Tilray Brands, Inc. | -244.98 Million USD | 96.788% |
| PetIQ, Inc. | 2.13 Million USD | 469.31% |
| Talphera, Inc. | -18.39 Million USD | 57.221% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 103.152% |
| Alimera Sciences, Inc. | -20.13 Million USD | 60.908% |
| Assertio Holdings, Inc. | -331.94 Million USD | 97.629% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -19.374% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 95.09% |
| Hempacco Co., Inc. | -13.12 Million USD | 40.043% |
| Alvotech | -551.73 Million USD | 98.574% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 102.409% |
| Kamada Ltd. | 8.28 Million USD | 195.002% |
| Currenc Group, Inc. | -15.3 Million USD | 48.584% |
| Indivior PLC | 2 Million USD | 493.5% |
| Evoke Pharma, Inc. | -7.79 Million USD | -0.997% |
| Flora Growth Corp. | -57.03 Million USD | 86.202% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 60.762% |
| Evolus, Inc. | -61.68 Million USD | 87.242% |
| HUTCHMED (China) Limited | 100.78 Million USD | 107.809% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 105.722% |
| Akanda Corp. | -32.27 Million USD | 75.616% |